These data support the hypothesis that in centers devoted to the management of pituitary diseases the choice of second-line therapies may be guided by biochemical markers (as GH and IGF-I levels) and by the tumor mass features (such as invasiveness and residual disease) rather than by the occurrence of systemic complications of acromegaly, such as diabetes mellitus. This evidence concerns the gene GH1 and neoplasm.